You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 11,712,459

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,712,459

Title:	Dosing regimens for treatment of fungal infections
Abstract:	The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
Inventor(s):	Kenneth BARTIZAL, Paul Daruwala, Jeffrey Brian LOCKE, Voon Ong, Taylor SANDISON, Dirk Thye
Assignee:	NAPP PHARMACEUTICAL GROUP Ltd
Application Number:	US16/084,600
Patent Claims:	1. A method of treating invasive candidiasis in a subject, wherein the method consists of: (i) (a) intravenously administering a first dose comprising 400 mg of CD101 in salt or neutral form, (b) intravenously administering a second dose comprising 200 mg of CD101 in salt or neutral form, and (c) optionally intravenously administering a third dose comprising 200 mg of CD101 in salt or neutral form, wherein the first dose is administered on day 1, the second dose is administered on day 8, and the third dose, if administered, is administered on day 15; and wherein the CD101 is administered as an aqueous pharmaceutical composition over a time period of 30 to 180 minutes or (ii) (a) intravenously administering a first dose comprising 400 mg of CD101 in salt or neutral form, (b) intravenously administering a second dose comprising 400 mg of CD101 in salt or neutral form, and (c) optionally intravenously administering a third dose comprising 400 mg of CD101 in salt or neutral form, wherein the first dose is administered on day 1, the second dose is administered on day 8, and the third dose, if administered, is administered on day 15; and wherein the CD101 is administered as an aqueous pharmaceutical composition over a time period of 30 to 180 minutes. 2. The method of claim 1, wherein the third dose is administered if on day 15 mycological eradication and/or clinical cure is not achieved in the subject or if on day 15 the subject displays symptoms of a fungal infection. 3. The method of claim 1, wherein the CD101 salt is CD101 acetate. 4. The method of claim 1, wherein the invasive candidiasis is candidemia.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.